Ligand Pharmaceuticals Overview
Ligand Pharmaceuticals Target Price
Analysts' 12-month price predictions for LGND.
Get informed when a big investor buys or sells
+ FollowShare Price
$319.55
Average Target Price
$259.75
18.7% downside
18.7% downside4 analysts in the last 4 months
High: $289 | Low: $243
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-04-30 | H.C. WainwrightJoseph Pantginis | $289 | 9.6% downside |  |
| 2026-04-28 | RBC Capital | $252 | 21.1% downside | |
| 2026-04-27 | Stifel Nicolaus | $255 | 20.2% downside | |
| 2026-04-14 | H.C. WainwrightJoseph Pantginis | $243 | 24% downside | |
| 2026-02-24 | H.C. WainwrightJoseph Pantginis | $239 | 25.2% downside | |
| 2025-12-10 | Stifel Nicolaus | $230 | 28% downside | |
| 2025-12-10 | OppenheimerTrevor Allred | $275 | 13.9% downside | |
| 2025-11-06 | Stifel NicolausAnnabel Samimy | $220 | 31.2% downside | |
| 2025-11-06 | H.C. Wainwright | $231 | 27.7% downside | |
| 2025-11-03 | OppenheimerLeland Gershell | $250 | 21.8% downside | |
| 2025-09-03 | OppenheimerLeland Gershell | $190 | 40.5% downside | |
| 2025-08-28 | H.C. Wainwright | $206 | 35.5% downside | |
| 2025-02-28 | UBS | $155 | 51.5% downside | |
| 2024-10-21 | H.C. WainwrightJoseph Pantginis | $157 | 50.9% downside | |
| 2024-10-02 | OppenheimerLeland Gershell | $135 | 57.8% downside | |
| 2024-07-30 | RBC CapitalDouglas Miehm | $130 | 59.3% downside | |
| 2024-07-09 | Craig-HallumMatt Hewitt | $140 | 56.2% downside | |
| 2024-06-28 | H.C. WainwrightJoseph Pantginis | $144 | 54.9% downside | |
| 2022-12-23 | Roth Capital | $90 | 71.8% downside | |